Concord Biotech Bonus Shares are set to be issued in a 1:1 ratio, giving eligible shareholders one additional fully paid-up equity share for every existing share held.
The company has fixed November 4, 2026, as the record date to determine which investors will receive the bonus shares.
The announcement has brought the company’s stock into focus ahead of Diwali. Concord Biotech confirmed the record date through a regulatory filing following its board meeting on October 27, 2026.
 Concord Biotech Bonus Shares: What Is the Record Date?
The company has fixed Wednesday, November 4, 2026, as the record date for its 1:1 bonus issue.
Shareholders whose names appear as eligible holders in the company’s records on the relevant date will qualify for the additional shares.
Under the announced ratio, investors will receive one bonus share for every one fully paid-up equity share held.
For example, an investor holding 100 eligible shares will receive 100 additional shares, taking the total holding to 200 shares after the bonus allotment.
The bonus issue was initially approved by the board on September 23, 2026. The record date was subsequently confirmed at the October 27 board meeting.
How Does the 1:1 Bonus Share Issue Work?
A 1:1 bonus issue means that the company will allot one additional share for every existing eligible share. These shares are issued without requiring shareholders to make an additional payment.
For example, an investor holding 50 Concord Biotech shares before the bonus issue will be entitled to receive 50 bonus shares. After the allotment, the investor’s total holding will become 100 shares.
However, a bonus issue does not automatically double the value of an investor’s investment.
The market price generally adjusts after the stock trades on an ex-bonus basis because the number of outstanding shares increases.
When Will Concord Biotech Shares Trade Ex-Bonus?
The company has fixed November 4, 2026, as the record date. The stock will trade on an ex-bonus basis from the applicable date announced by the stock exchange.
Under the T+1 settlement system, investors should pay attention to the ex-date and ensure that their shares are credited to their demat accounts in time to qualify.
Investors should check the exchange’s corporate action notice and their broker’s information before making any transaction.
The bonus issue is expected to result in the allotment of 10,46,16,204 additional equity shares, according to the exchange notice.
What Should Concord Biotech Shareholders Know?
Existing shareholders should understand that bonus shares increase the number of shares in their demat accounts but do not represent an immediate cash payment.
The adjustment in the share price after the ex-bonus date is a normal feature of a bonus issue.
Investors should therefore consider their overall investment value rather than looking only at the number of shares held.
The bonus issue is a corporate action and should not be treated as a guaranteed opportunity for short-term gains.
Investors should review the company’s financial performance, business outlook and market conditions before making investment decisions.
Concord Biotech’s bonus issue has attracted attention ahead of Diwali, but eligibility depends on the official record-date requirements and exchange settlement rules.
